Kornimate/medical-research-clean huggingface dataset:
the value of traction in the treatment of cervical radiculopathy

Conditions: Radiculopathy; Neck Pain; Spinal Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Intervertebral Disk Displacement

Summary: the purpose of this study is to determine the effectiveness of adding mechanical traction to standard physical therapy treatments for patients with neck and arm pain.

cervical traction is an intervention frequently recommended for the treatment of patients with neck pain. systematic reviews have not endorsed the use of mechanical traction for patients with neck pain, however these reviews note the poor methodological quality of available research. trials that have been performed have examined heterogeneous samples of patients with neck pain. it may be that cervical traction has not shown to be effective because only a specific subgroup may benefit from it. most experts believe that traction is most beneficial for individuals with neck pain extending into the upper extremity who have signs of nerve root compression. randomized clinical trials examining the effectiveness of traction for patients with these specific characteristics have not been performed. preliminary studies support the hypothesis that there exists a specific subgroup of patients with neck pain likely to benefit from traction the current study will address 3 important questions: 1. will the existence of a more specific subgroup of patients who benefit from traction along with a standard exercise program be validated in a second sample of patients? 2. is cervical traction a critical component of the treatment necessary to maximize outcomes for patients in this subgroup? 3. do two commonly used traction protocols differ in their effectiveness for patients in this subgroup? (specifically, we study will compare supine mechanical traction to over-the-door traction.)

Eligibility criteria:
inclusion criteria: 1. primary complaint of neck pain with symptoms (pain and/or numbness) extending distal to the acromioclavicular joint or caudal to the superior border of the scapula (may be unilateral or bilateral). 2. age between 18-70 years old 3. neck disability score score \>10 points exclusion criteria: 1. red flags indicative of a serious or non-musculoskeletal condition (i.e. tumor, fracture, metabolic diseases, ra, osteoporosis, prolonged history of steroid use, etc.) 2. diagnosis of cervical spinal stenosis based on ct or mri imaging 3. evidence of cervical myelopathy or central nervous system involvement, (e.g., hyperreflexia, intrinsic muscle wasting of the hands, unsteadiness during gait, nystagmus, loss of visual acuity, impaired sensation of the face, altered taste, presence of pathologic reflexes (i.e. positive hoffman's or babinski reflex). 4. prior surgery to the neck or thoracic spine 5. inability to comply with treatment and follow-up schedule

Keywords: radiculopathy neck pain physical therapy modalities rehabilitation
the vascutek rapidax™ ii post market surveillance registry

Conditions: End Stage Kidney Disease

Summary: multicentre, prospective, observational post-market registry. to monitor and collect data on the post-market clinical safety and performance of the vascutek rapidax ii vascular access graft.

at least 10 patients who have been implanted with a rapidax ii vascular access graft for haemodialysis applications in patients with end stage renal disease (esrd), who are undergoing or are scheduled to begin haemodialysis and require implant of a prosthetic graft. primary end points:safety and performance * secondary patency at 6 months post implant (performance).(access survival until abandonment). the interval from time of implant to abandonment or time of measurement of patency, including intervention to re-establish the functionality of the thrombosed access * secondary patency at 12 months post implant (performance.(access survival until abandonment). the interval from time of implant to abandonment or time of measurement of patency, including intervention to re-establish the functionality of the thrombosed access * freedom from device related serious adverse events at 6 and 12 months (safety) secondary end points: safety and performance * primary patency at 6 months post implant (performance. (intervention free access survival). the interval from time of implant to any intervention designed to maintain or re-establish patency or to access thrombosis * primary patency at 12 months post implant (performance).(intervention free access survival). the interval from time of implant to any intervention designed to maintain or re-establish patency or to access thrombosis * assisted primary patency at 6 months (performance. (thrombosis free access survival). the interval from time of implant to intervention to maintain patency prior to the occurrence of thrombosis * freedom from device related serious adverse events at 6 and 12 months

Eligibility criteria:
inclusion criteria: 1. subject is ≥ 18 and ≤ 90 years old 2. subject has a life expectancy of at least 12 months 3. subject is scheduled to undergo placement of a new straight or loop arm arteriovenous haemodialysis access graft 4. the subject is willing and able to comply with the protocol and associated follow up requirements 5. subjects must have agreed for their data to be entered into the registry as per the local hospital consent procedure exclusion criteria: 1. known allergy or sensitivity to eptfe 2. subject unwilling or unable to comply with the protocol 3. life expectancy of less than 1 year

Keywords: vascular access grafts haemodialysis
correlation of mukbang video watching behavior,internet addition and mental health among general population

Conditions: Mukbang

Summary: this study will describe the general population's current situation of watching "mukbang" videos, their mental health status and the level of internet addiction tendency by means of an online survey, and analyze their correlations. it provides a theoretical basis for promoting healthy psychological development and standardizing management of "mukbang" videos.

mental health issues have always been the focus of health management. the lancet global commission on mental health and sustainable development also recommends a broad cross-sectoral approach to mental health issues. with the rapid development of short videos and self-media, watching "mukbang" is a behavioral way for netizens to alleviate mental health problems such as anxiety and depression. however, watching "mukbang" can be internet addictive. at present, there is no research to predict the addictive behavior caused by "mukbang", and there is no relevant research to explore its addiction mechanism. although it has been clear that internet addiction and mental health disorders are significantly related, there is no clear statement on whether there is a common risk factor, a mediating effect, or a causal relationship between the two. the behavior of watching "mukbang" videos may be in a mediating position between the two. this study will further explore the relationship between the three based on the use and satisfaction theory.

Eligibility criteria:
inclusion criteria: * internet users over the age of 18; * be able to read and communicate in chinese. exclusion criteria: * those who can not complete communication due to serious mental or physical diseases such as deafness, unclear consciousness caused by mental illness, etc.;

Keywords: mukbang mental health internet addiction
customized polyamide prosthesis. for mid shaft clavicle fracture

Conditions: Treatment Adherence and Compliance

Summary: herein we describe the management of a patient who presented with progressive brachial plexopathy following the initial nonoperative management of a mid shaft clavicular fracture by using 3 d customized polyamide prosthesis.

we made surgery to fix the new polyamide prosthesies in the clavicle.

Eligibility criteria:
inclusion criteria: * fracture midshaft clavicle exclusion criteria: * normal clavicle
a study to investigate the impact of abiraterone acetate and enzalutamide on health-related quality of life, participant-reported outcomes, and medical resource use in metastatic castration-resistant prostate cancer participants

Conditions: Prostatic Neoplasms

Summary: the purpose of this observational study of metastatic castration-resistant prostate cancer (mcrpc) participants is to explore whether or not there are differences between participants treated with abiraterone acetate and enzalutamide on the health-related quality of life (hrqol), fatigue, pain, cognitive function and medical resource use (mru).


Eligibility criteria:
inclusion criteria: * male 18 years of age or older * participant with histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate * participant with documented metastatic prostate cancer * participant with documented castration resistance with progression of prostate cancer on androgen deprivation therapy (adt) * participant who will be initiated on either abiraterone acetate or enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mcrpc) that is asymptomatic or mildly symptomatic (per physician's evaluation) after failure of adt at the time of treatment initiation * participants who signed a participation agreement or informed consent form (icf) per local regulations * the treatment decision (abiraterone acetate or enzalutamide) by the treating physician must have been taken before enrollment into the study * baseline patient-reported outcomes (pros) must be captured before the first administration of abiraterone acetate or enzalutamide. exclusion criteria: * patient who has received any chemotherapy/cytotoxic agent to treat their mcrpc before abiraterone acetate or enzalutamide initiation; or ; treat their metastatic hormone-sensitive prostate cancer (mhspc) \<12 months prior to abiraterone acetate or enzalutamide initiation. * participant who is not capable of completing a patient survey * participant who has received or is currently receiving abiraterone acetate or enzalutamide * patient receiving an investigational treatment for prostate cancer of any kind before or at the time of initiation of abiraterone acetate or enzalutamide * participant who is currently included in other observational studies with abiraterone acetate sponsored by janssen
molecular imaging of fap expressing cancer-associated fibroblasts in nsclc treated with immune-checkpoint inhibitors

Conditions: Non Small Cell Lung Cancer

Summary: evaluation of the relation between baseline fibroblast activation protein (fap) expression based on ga-fapi uptake with patient outcome among nsclc patients receiving immunotherapy for recurrent/metastatic disease.

fibroblast activation protein (fap), a type ii membrane glycoprotein, is selectively expressed by cancer-associated fibroblasts (cafs) in more than 90% of epithelial carcinomas. fap also regulates antitumor immune response. for these reasons, fap is an attractive target and molecular imaging biomarker to assess cafs and the tumour's landscape before and during immunotherapy. the pet radiotracer 68ga-fapi (fibroblast activation protein inhibitor) allows the visualisation and quantification of cafs.this study will use a non-invasive technique to assess cafs before and during immunotherapy and to evaluate diverse predictive biomarkers in a prospective setting studying simultaneously cafs (using 68ga-fapi) and cfdna.

Eligibility criteria:
inclusion criteria: * age above 18 years. * pathologically- proven non-small-cell lung cancer (nsclc). * proposed for treatment with anti-pd-(l)1 alone or in combination with chemotherapy and/or anti-ctla4 in the advanced setting. * ecog performance status ≤2. * patient's written informed consent obtained prior to any study procedure. exclusion criteria: * surgery and/or radiotherapy to thoracic region within the last 8 weeks or anti-cancer systemic therapy within the last 2 weeks. * epidermal growth factor receptor (egfr), anaplastic lymphoma kinase (alk) and c-ros oncogene (ros1) mutations. * pregnant and lactating women * previous or concurrent malignancy diagnosed within the last 2 years except adequately treated in situ carcinoma of the cervix uteri, localised (t1n0) low grade (gleason score 6) prostate cancer undergoing active surveillance and basal or squamous cell skin cancer. * subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.

Keywords: immunotherapy fapi-46 non small cell lung cancer pet pet/ct fibroblast activation protein fibroblast activation protein inhibitor
bacterial sexually transmitted infections (stis) viability by polymerase chain reaction (pcr)

Conditions: Men Who Have Sex With Men

Summary: it is a cross-sectional, without risk or constraint, monocentric study on the viability of the main bacterial sexually transmitted infections (stis) in men who have sex with men (msm). the main objective is to evaluate the proportion of pharyngeal, urogenital and anal specimens detected positive by nucleic acid amplification test (naat) for chlamydia trachomatis, neisseria gonorrhoeae and mycoplasma genitalium that contain viable bacteria in msm.

screening for c. trachomatis and n. gonorrhoeae stis at 3 anatomical sites, i.e. pharyngeal, urogenital and anal, is recommended every three to six months in msm with high-risk sexual behaviors, using naat. a positive naat result defines the patient as infected, and the patient will receive antibiotic treatment. however, repeated use of antibiotics has led to the emergence of multi-drug resistant strains of m. genitalium, another sti agent, and n. gonorrhoeae, and to changes in the gut microbiota. one disadvantage of naats is that they amplify the nucleic acids of viable and dead bacteria. thus, it is not possible to affirm that the patient has an "active" infection, defined by the presence of viable bacteria. bacterial viability can be studied by real-time pcr (called v-pcr). this method combines the high sensitivity and specificity of pcr with the ability to exclude detection of nucleic acid remnants from non-viable bacteria. it does so by incorporating a sample pretreatment step with a membrane impermeable dna intercalating dye prior to molecular analysis by blocking amplification of remnant dna from non-viable bacteria. this allows the v-pcr analysis to detect dna originating from intact (i.e. viable) bacteria. using v-pcr, studies in women have shown that only half of the anorectal samples and one quarter of the pharyngeal samples positive for c. trachomatis contain viable bacteria. the team proposes to investigate the presence of viable c. trachomatis, n. gonorrhoeae and m. genitalium bacteria by v-pcr in pharyngeal, urogenital and anal specimens from msm detected as positive by naat for these bacteria. the results of this work will allow us to assess whether all types of specimens tested in these patients contain viable bacteria, and if so, in what proportions.

Eligibility criteria:
inclusion criteria: * males \> 18 years * men who have sex with men * participant consulting at the bordeaux university hospital * oral consent to participate in the study * member or beneficiary of a social security system exclusion criteria: * participant \< 18 years * participant subject to a legal protection measure (protection of the court, guardianship or curator). * participant deprived of liberty by judicial or administrative decision.

Keywords: chlamydia trachomatis neisseria gonorrhoeae mycoplasma genitalium viability pcr nucleic acid amplification tests
gastric cancer risk factors knowledge in european and latinamerican population

Conditions: Gastric Cancer

Summary: this study is divided into two parts: part 1: an interventional study, with a pre-post study design to determinate the grade of knowledge of established gc risk factors. part 2: an observational study to know impact on prevalence and infection eradication of h. pylori

part 1: to determinate the grade of knowledge of established gc risk factors and identification of attitudes about, gc screening programs at baseline, prior to the intervention though an educational program. part 2: to generate an h. pylori registry, to know its impact on prevalence and infection eradication rate at 6th, 12th, 24th and at month 36th.

Eligibility criteria:
part a: educational intervention inclusion criteria * subjects \>18 years old, from eu and celac countries participating in this study. * has given and signed the ic to participate in this study. exclusion criteria * subjects who have received some prior preparation (cancer gastric information). * subjects who have previous knowledge in gastric cancer (example, near relatives who have suffered gastric cancer part b: h. pylori register inclusion criteria * subjects ≥18 years old diagnose from h. pylori infection and treated at participant sites * has given and signed the ic. exclusion criteria * subjects with chronic gastritis without confirmed diagnose of h. pylori infection, pathologically of by urease test. * patient's with cg diagnosis (including gastroesophageal junction cancer).

Keywords: gastric cancer personalized medicine oncology solid tumor primary intervention
treatment with sitagliptin in non-obese japanese patients with type 2 diabetes mellitus

Conditions: Type 2 Diabetes

Summary: type 2 diabetes mellitus (t2dm) results from early phase insulin secretory defect and insulin resistance. studies have shown that most of the populations in which insulin resistance is considered to be the primary pathogenetic cause of diabetes, have a higher degree of obesity than those of primary insulin defect. meanwhile, defective early insulin secretion plays a predominant role in the non-obese subtype of t2dm which includes majority of japanese patients. sitagliptin is a dipeptidyl peptidase-4 (dpp-iv) inhibitor as indicated for the treatment of t2dm. sitagliptin increases plasma concentrations of active glucagon-like peptide-1 (glp-1) and active glucose-dependent insulinotropic peptide (gip) two- to three-fold in patients with t2dm. the effect of sitagliptin on glp-1 results in lower fasting and postprandial glucose concentrations through increases in glucose dependent insulin release and suppression of inappropriate glucagon secretion. namely, several mechanistic studies using standardized meal showed that sitagliptin improved glucose control with decreased glucagon levels and increased insulin concentration in obese or overweight t2dm patients with bmi \> 25 kg/m2. however, how sitagliptin affects islet function, including glucagon secretion in non-obese patients with low insulin secretion are not known. therefore, the investigators will examine the effect of sitagliptin on glycemic control and the mechanism involved using a standardized test meal in non-obese japanese patients with t2dm whose bmi levels are \< 25 kg/m2.


Eligibility criteria:
inclusion criteria: * type 2 diabetic patients * non-obese patients exclusion criteria: * patients treated with insulin therapy * patients aged less than 20 years and more than 90 years
sevuparin infusion for the management of acute voc in subjects with scd

Conditions: Sickle-Cell Disease

Summary: a multi-centre, phase ii, randomized, double-blind, placebo-controlled study to investigate efficacy and safety of sevuparin infusion for the management of acute vaso-occlusive crisis (voc) in subjects with sickle-cell disease (scd).

this will be a phase ii, multi-centre, randomized, double-blind, placebo-controlled study designed to assess preliminary efficacy, safety and pharmacokinetics (pk) of 2-7 days continuous iv administration of sevuparin for the management of acute voc in subjects with scd. adults and adolescents ≥ 12 years of age will be randomized to treatment with sevuparin or placebo (ratio 1:1).

Eligibility criteria:
inclusion criteria: * sign a written informed consent (adults, parents) and assent (adolescents) * male or female, age 12-50 years. * diagnosis of sickle cell disease * subjects admitted for an acute, painful voc to be treated/or treated with parenteral opioid analgesia. * expectancy of need for hospitalization during at least 48 hours. * be at least 1 year postmenopausal, surgically sterile, or if women of child bearing potential (wocbp), e.g. following menarche practicing an effective method of birth control exclusion criteria: * severe hepatic failure/disease, abnormal liver enzyme tests or history of hepatitis b virus (hbv), hepatitis c virus (hcv) * abnormal conjugated (direct) bilirubin 3 fold above uln * history of clinically significant bleeding in vital organs * current clinically significant bleeding, as judged by the investigator * current use of acetylsalicylic acid (asa), anti-platelet therapy, anticoagulant therapy * abnormal coagulation laboratory values * a platelet count \<75,000/µl. * bmi \>35 * subjects with more than 5 hospitalizations for voc during the last 6 months * evidence of acute scd complications other than voc at screening * the use of strong opioids for \> 3 consecutive days during the last 15 days before presenting to the hospital * history of chronic drug abuse. * renal dysfunction * known infection (positivity) with human immunodeficiency virus (hiv), hbv or hcv. * significant ecg abnormality * history of a clinically significant drug allergy to heparin, lmwh's, sevuparin, or morphine. * use of any investigational agent during the 30 days prior to the first dose. * for females: pregnancy, lactating or intention of becoming pregnant * evidence of clinically significant disorders that might interfere with the study aim or safety of the subject * any condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study.
efficiency of the super inductive system in spasticity treatment

Conditions: Spasticity, Muscle

Summary: the aim of the study is to see whether a physical therapy program can relieve pain, decrease spasticity and increase muscle contraction force by using the super inductive system (high frequency electromagnetic field). it is a longitudinal, prospective study, of 60 patients with spasticity after stroke. no new treatment method is tested, as the super inductive system is approved for physical therapy by the ministry of health.

the 60 patients will be submitted to 2 treatment groups: 30 patients will receive 10 sessions of the superinductive system on the antagonist muscles, and 30 patients will receive 10 sessions the superinductive system on the agonist and antagonist muscles. all patients will also receive the standard kinetotherapy program for spasticity. the patients will be evaluated at the beginning of the treatment, at 10 days and at 30 days by using the functional mas index and barthel index.

Eligibility criteria:
inclusion criteria: * spasticity after stroke exclusion criteria: * spasticity of other causes